Working… Menu
Trial record 68 of 80 for:    "curcumin" and "cancer"

Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01269203
Recruitment Status : Withdrawn
First Posted : January 4, 2011
Last Update Posted : September 7, 2012
National Institutes of Health (NIH)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
The goal of this clinical research study is to learn if curcumin can reduce the symptoms reported by patients with multiple myeloma (MM) who receive treatment with lenalidomide.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Curcumin Other: Placebo Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Study of the Efficacy of Curcumin for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
Study Start Date : October 2012
Estimated Primary Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Curcumin

Arm Intervention/treatment
Active Comparator: Curcumin
1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
Drug: Curcumin
1000 mg per day

Placebo Comparator: Placebo
Placebo daily + 5 -15 mg/day Lenalidomide
Other: Placebo
Administered daily same as Curcumin.

Primary Outcome Measures :
  1. AUC from 3 months Post-Transplantation to 9 months Post-Transplantation [ Time Frame: Assessments within +/-3 days of 4 week cycle start date for 6 cycles. ]
    Daily area under the curve (AUC) where AUC is based on average of 5 most severe symptoms (pain, fatigue, bone aches, numbness, disturbed sleep) being experienced by MM patients as measured by MDASI-MM, a multiple-symptom measure of cancer-related symptoms rate severity of physical, affective, and cognitive symptoms on 0-10 numeric scales, ranging from 0 "not present" to 10 "as bad as you can imagine."

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must have a histologically confirmed diagnosis of multiple myeloma.
  2. Must be >/= 18 years of age.
  3. Must have a performance status (ECOG PS) of 0-2.
  4. Must be qualified and have signed consent to receive lenalidomide for maintenance therapy for MM.
  5. Must have signed informed consent indicating that they are aware of the investigational nature of the study, and are aware that participation is voluntary.
  6. Must also agree to refrain from use of self prescribed curcumin during the course of the study.
  7. Must have negative pregnancy test before signing consent for MM therapy.

Exclusion Criteria:

  1. Unable to understand the symptom assessment or not willing to participate in the study.
  2. Treatment for other carcinomas within the last 5 years, except for cured non-melanoma skin and treated in-situ cervical cancer.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or requiring IV antibiotics, cardiac disease (NYHA class III or IV heart failure), unstable angina pectoris, unstable cardiac arrhythmia or tachycardia, or psychiatric illness/ social situations that would limit compliance with the study requirements are excluded.
  4. Concurrent use of coumadin other than low dose (1 mg) coumadin used for line patency.
  5. Concurrent use of cimetidine, allopurinol, or aluminium hydroxide and magnesium hydroxide-containing antacids such as Maalox.
  6. Sorivudine and brivudine use within 4 weeks of the start of study treatment.
  7. Gastric or duodenal ulcers, or gastric hyperacidity disorders.
  8. Currently receiving anticoagulants (heparin) or antiplatelets (clopidogrel, ticlopidine, aspirin/dipyridamole)
  9. INR > 1.5 (upper limit of normal = 1.5).
  10. History of deep vein thrombosis.
  11. Received allogeneic transplant.
  12. Allergy to turmeric, Curcumin, or yellow dye.
  13. Bowel or bile duct obstruction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01269203

Sponsors and Collaborators
M.D. Anderson Cancer Center
National Institutes of Health (NIH)
Layout table for investigator information
Study Chair: Robert Orlowski, MD, PhD UT MD Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01269203     History of Changes
Other Study ID Numbers: 2010-0457
First Posted: January 4, 2011    Key Record Dates
Last Update Posted: September 7, 2012
Last Verified: September 2012
Keywords provided by M.D. Anderson Cancer Center:
tumor necrosis factor
multiple myeloma
maintenance therapy
bone marrow transplantation
Autologous Hematopoietic Stem Cell Transplantation
NF-kB inhibition
reducing symptoms
maintenance chemotherapy
inflammatory cytokines
nuclear factor kappa B
NF-kB activation levels
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Multiple Myeloma
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents